{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T07:23:54Z","timestamp":1770708234210,"version":"3.49.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["dldjournalonline.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.dld.2017.06.008","type":"journal-article","created":{"date-parts":[[2017,6,23]],"date-time":"2017-06-23T05:00:29Z","timestamp":1498194029000},"page":"1043-1049","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Tolerance and outcomes of sorafenib in elderly patients treated for advanced hepatocellular carcinoma"],"prefix":"10.1016","volume":"49","author":[{"given":"Nicolas","family":"Williet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3450-1228","authenticated-orcid":false,"given":"L\u00e9a","family":"Clavel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aur\u00e9lie","family":"Bourmaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9line","family":"Verot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia","family":"Bouarioua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Roblin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Merle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Marc","family":"Phelip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2017.06.008_bib0005","unstructured":"Globocan 2012 \u2014 Home n.d. http:\/\/globocan.iarc.fr\/Default.aspx. [Accessed 10 October 2016]."},{"key":"10.1016\/j.dld.2017.06.008_bib0010","first-page":"4067","article-title":"Type 2 diabetes and risk of pancreatic adenocarcinoma","volume":"31","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.dld.2017.06.008_bib0015","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1200\/JCO.2012.48.4410","article-title":"Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study","volume":"31","author":"Johnson","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.dld.2017.06.008_bib0020","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1200\/JCO.2012.47.3009","article-title":"Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study","volume":"31l","author":"Llovet","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.dld.2017.06.008_bib0025","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1001\/jama.2014.7189","article-title":"Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial","volume":"312","author":"Zhu","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.dld.2017.06.008_bib0030","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S1470-2045(15)00050-9","article-title":"Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial","volume":"16","author":"Zhu","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.dld.2017.06.008_bib0035","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1200\/JCO.2013.54.3298","article-title":"Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial","volume":"33","author":"Cainap","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"Suppl","key":"10.1016\/j.dld.2017.06.008_bib0040","article-title":"Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance)","volume":"34","author":"Abou-Alfa","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.dld.2017.06.008_bib0045","unstructured":"Abou-Alfa G, Qin S, Ryoo B-Y, et al. Phase III randomized study of second-line ADI-peg 20 (A) plus best supportive care versus placebo (P) plus best supportive care in patients (pts) with advanced hepatocellular carcinoma (HCC). n.d."},{"key":"10.1016\/j.dld.2017.06.008_bib0050","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis","volume":"64","author":"Wilhelm","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.dld.2017.06.008_bib0055","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s00280-006-0393-4","article-title":"Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models","volume":"59","author":"Chang","year":"2007","journal-title":"Cancer Chemo. Pharmacol."},{"key":"10.1016\/j.dld.2017.06.008_bib0060","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.dld.2017.06.008_bib0065","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.dld.2017.06.008_bib0070","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.2217\/fon.15.163","article-title":"Impact of sorafenib dosing on outcome from the European patient subset of the GIDEON study","volume":"11","author":"Daniele","year":"2015","journal-title":"Future Oncol. (London, England)"},{"issue":"January 1","key":"10.1016\/j.dld.2017.06.008_bib0075","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/MEG.0000000000000739","article-title":"Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: age is not a problem","volume":"29","author":"Ziogas","year":"2017","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.dld.2017.06.008_bib0080","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1155\/2013\/170546","article-title":"In a \u201creal-world\u201d, clinic-based community setting, sorafenib dose of 400mg\/day is as effective as standard dose of 800mg\/day in patients with advanced hepatocellular carcimona, with better tolerance and similar survival","volume":"27","author":"Shingina","year":"2013","journal-title":"Can. J. Gastroenterol."},{"key":"10.1016\/j.dld.2017.06.008_bib0085","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.2217\/fon.14.68","article-title":"EASL HCC summit: liver cancer management","volume":"10","author":"Sacco","year":"2014","journal-title":"Future Oncol. (London, England)"},{"key":"10.1016\/j.dld.2017.06.008_bib0090","series-title":"R: a language and environment for statistical computing","author":"R Core Team","year":"2014"},{"key":"10.1016\/j.dld.2017.06.008_bib0095","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1634\/theoncologist.2011-0192","article-title":"The outcomes and safety of single-agent sorafenib in the treatment of elderly patients with advanced hepatocellular carcinoma (HCC)","volume":"16","author":"Wong","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.dld.2017.06.008_bib0100","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1111\/jgs.13091","article-title":"Safety of sorafenib therapy in elderly adults with advanced hepatocellular carcinoma","volume":"62","author":"Francini","year":"2014","journal-title":"J. Am. Geriatrics Soc."},{"key":"10.1016\/j.dld.2017.06.008_bib0105","doi-asserted-by":"crossref","first-page":"e0117168","DOI":"10.1371\/journal.pone.0117168","article-title":"Comparison of treatment safety and patient survival in elderly versus nonelderly patients with advanced hepatocellular carcinoma receiving sorafenib combined with transarterial chemoembolization: a propensity score matching study","volume":"10","author":"Hu","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.dld.2017.06.008_bib0110","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1007\/s12032-012-0446-y","article-title":"Impact of age on toxicity and efficacy of sorafenib-targeted therapy in cirrhotic patients with hepatocellular carcinoma","volume":"30","author":"Di Costanzo","year":"2013","journal-title":"Med. Oncol. (Northwood, London, England)"},{"key":"10.1016\/j.dld.2017.06.008_bib0115","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1159\/000345558","article-title":"Sorafenib in elderly patients with advanced hepatocellular carcinoma: a case series","volume":"84","author":"Montella","year":"2013","journal-title":"Oncology"},{"key":"10.1016\/j.dld.2017.06.008_bib0120","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1111\/hepr.12308","article-title":"Efficacy and safety of sorafenib in very elderly patients aged 80 years and older with advanced hepatocellular carcinoma","volume":"44","author":"Jo","year":"2014","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.dld.2017.06.008_bib0125","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1159\/000320223","article-title":"Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access program","volume":"78","author":"Bukowski","year":"2010","journal-title":"Oncology"},{"key":"10.1016\/j.dld.2017.06.008_bib0130","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1872-034X.2011.00778.x","article-title":"Higher discontinuation and lower survival rates are likely in elderly Japanese patients with advanced hepatocellular carcinoma receiving sorafenib","volume":"41","author":"Morimoto","year":"2011","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.dld.2017.06.008_bib0135","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2147\/JHC.S101448","article-title":"Hepatocellular carcinoma in elderly patients: challenges and solutions","volume":"3","author":"Brunot","year":"2016","journal-title":"J. Hepatocell. Carcinoma"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865817309386?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865817309386?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,31]],"date-time":"2018-08-31T09:20:44Z","timestamp":1535707244000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865817309386"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":27,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S1590865817309386"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2017.06.008","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tolerance and outcomes of sorafenib in elderly patients treated for advanced hepatocellular carcinoma","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2017.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}